| Document |
Document Title |
|
WO/2018/034669A1 |
The present invention is directed to packaging films comprising an antioxidant based on 4-pyranone having a general structural formula: Formula (I).
|
|
WO/2018/029264A1 |
Processes for the preparation of dapagliflozin reduce or eliminate impurities in dapagliflozin, preferably individual impurities are not more than 0.15% by HPLC.
|
|
WO/2018/029611A1 |
The present invention generally relates to an improved process for the preparation of dapagliflozin of Formula I or its solvates or co-crystals thereof. The present invention also encompasses the novel intermediates and their use in the ...
|
|
WO/2017/216791A9 |
Provided herein is a conjugate comprising two residues of structurally and/or mechanistically different anticancer bioactive agents, coupled to one another by a biocleavable linking moiety, as well as methods of treating cancer using the...
|
|
WO/2018/019549A1 |
The invention discloses 2-((2R,4R)-4-(4-(benzyloxy)-4-methylpent-2-yn-1-yl)-2-(tert-
butyl)-5-oxo-1,3-dioxolan-4-yl)acetic acid of formula (XIX), a process for its preparation and processes for its conversion into enantiomerically pure (...
|
|
WO/2018/014866A1 |
Disclosed are a crystal form of a dapagliflozin intermediate and a preparation method therefor, and specifically disclosed are a crystal form of the dapagliflozin intermediate (2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-2-eth
...
|
|
WO/2017/221211A1 |
The present invention provides for crystalline Dapagliflozin butane –1,2– diol solvate (VIII), crystalline Dapagliflozin (S) butane –1,2– diol solvate (VIIIa) and Dapagliflozin (R) butane –1,2– diol solvate (VIIIb). The prese...
|
|
WO/2017/219510A1 |
A quinoid chalcone c-glycoside dimer compound having an anti-tumor activity and an anti-inflammatory activity and a method for preparing same. The compound is a quinoid chalcone c-glycoside dimer compound separated from Carthamus tinctor...
|
|
WO/2017/206808A1 |
Provided is a process for preparing a dapagliflozin eutectic, comprising: 1) using a 4-chloro-3-(4-ethoxybenzyl)phenyl halide 6 as a raw material, reacting 6 with lithium alkylide and a zinc salt via an X/Li/Zn exchange reaction in an ap...
|
|
WO/2017/206827A1 |
Disclosed are a crystal form of an L-proline cocrystal of a sodium-glucose cotransporter 2 inhibitor, a preparation method therefor, and a pharmaceutical composition and a use therof. Particularly involved are the crystal form of the L-p...
|
|
WO/2017/207539A1 |
The invention relates to tetrahydropyranyl lower alkyl esters and particularly tetrahydropyranyl acetates, a method for producing same using ketene, and the use of same as fragrant and aromatic substances.
|
|
WO/2017/202365A1 |
Provided are a preparation method for a trifluoromethyl-substituted pyran derivative and an intermediate thereof, namely, a preparation method for a compound as shown in formula (I) and an intermediate thereof. The method is characterize...
|
|
WO/2017/202644A1 |
The present invention relates to methods of forming delta-lactone compounds by reaction of a diene with carbon dioxide in the presence of Pd and a phosphine ligand.
|
|
WO/2017/202264A1 |
Disclosed are a new dapagliflozin crystal form and a preparation method and use thereof. In particular, disclosed are a crystal form E of 2-chloro-5-(β-D-glucopyranose-1-yl)-4'-ethyoxyldiphenylmeth
ane and a preparation method therefor,...
|
|
WO/2017/202357A1 |
Provided is a method for preparing a trifluoromethyl-substituted pyran derivative, that is, a method for preparing the compound shown in formula (I) and an intermediate thereof. The method has the advantages of having mild reaction condi...
|
|
WO/2017/201407A1 |
A hydrogel particle comprising: cross-linked dextran aldehyde (oxidized dextran), comprising the redox sensitive disulfide cross-linker cystamine (2,2'-disulfanediyldiethanamine), the anti-tumor agent doxorubicin conjugated to the cross-...
|
|
WO/2017/198202A1 |
Disclosed are a novel polycrystalline form of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-me
thyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2
-indolinone (nintedanib), a manufacturing method thereof, and a pharm...
|
|
WO/2017/192304A1 |
The present disclosure is directed to compounds of formula (I): or a pharmaceutically acceptable salt, solvate or solvate of the salt thereof. Compounds of formula (I) are inhibitors of NOX4 and are useful in the treatment of fibrotic di...
|
|
WO/2017/187859A1 |
The present invention is a compound represented by formula (1), a liquid crystal composition containing the compound, and a liquid crystal display element including the composition. In the formula: R is a C1-15 alkyl or the like; ring A1...
|
|
WO/2017/184984A1 |
Molecular characterization of disease has become the dominant trend in modern medicine, and it has recently become increasingly important to obtain qPCR, microarray, and next-generation sequencing (NGS) data for both research and clinica...
|
|
WO/2017/183723A1 |
The present invention addresses the problem of providing a novel compound having a strong opening action with respect to KCNQ 2-5 channels. Provided is a compound represented by the general formula (I) (in the formula, the definitions of...
|
|
WO/2017/183581A1 |
Provided are a composition and the like having Tie2 activation effect, vascular permeability suppression effect, vascular maturation effect, vascular normalization effect, vascular stabilization effect, lymph vessel stabilization effect,...
|
|
WO/2017/174827A1 |
The invention relates primarily to the use of one or more stereoisomers of compounds of formula (I) for modifying and/or intensifying the odour sensation of one or more aromas with a lily of the valley scent. The invention also relates t...
|
|
WO/2017/167969A1 |
Methods for producing ferric maltol compositions, such as ferric trimaltol, from elemental iron, andferric maltol compositions produced by these methods and their usesare described.
|
|
WO/2017/167963A1 |
Methods for producing ferric maltol compositions, such as ferric trimaltol,are described in which maltolis reacted with a ligand modified ferric hydroxide and/or a ligand coated ferric hydroxide.
|
|
WO/2017/170859A1 |
The purpose of the present invention is to provide a compound that inhibits the collagen binding function of an HSP47 essential for the extracellular secretion of collagen. The present invention provides a bisaryl derivative indicated by...
|
|
WO/2017/167970A1 |
Methods for producing ferric maltol compositions, such as ferric trimaltol, from ferrous hydroxides, are described, as well as ferric maltol compositions produced by these methods and their uses.
|
|
WO/2017/160925A1 |
Disclosed herein are compounds of Formulae (I), and (II), methods of synthesizing compounds of Formulae (I) and (II), and methods of using compounds of Formulae (I) and (II) as an analgesic.
|
|
WO/2017/156194A1 |
There are provided inter alia metalloenzyme inhibitors, such as inhibitors of influenza A RNA dependent RNA polymerase PA subunit endonuclease, and methods of synthesis and use of the same.
|
|
WO/2017/156354A1 |
The present invention provides a compound, and method of inhibiting the activity of a Fatty Acid Binding Protein (FABP) comprising contacting the FABP with a compound, said compound having the structure : Formula (I)
|
|
WO/2017/138838A1 |
The invention relates to salts and hydrates of arylcycloalkylamine derivatives of general formula (I) and formula (II), where in formula (I), R1 and R2 signify H, a linear or branched alkyl (C1, C4), a linear or branched alkoxy (C1, C4),...
|
|
WO/2017/133675A1 |
The present invention relates to a method for preparing a high-purity cyclohexenone long-chain alcohol represented by formula I. The compound represented by formula I is prepared by using metal-mediated Barbier reaction. The method of th...
|
|
WO/2017/131221A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a and R4b are as defined in the specification, processes for their preparation, pharmaceutical compositions cont...
|
|
WO/2017/130148A1 |
The present disclosure relates to an in vitro method for enhancing engraftment of neurosensory precursor cell comprising the step of contacting an isolated neurosensory precursor cell prior to a transplantation in a subject in need there...
|
|
WO/2017/126275A1 |
The means according to the present invention are: a compound represented by formula (1); a liquid crystal composition containing this compound; and a liquid crystal display element comprising this composition. In formula (1), each of R1 ...
|
|
WO/2017/125775A1 |
The present invention relates to the use of a pyrenocine compound or a pyrenochaetic acid compound for the prevention or the treatment in algae of diseases induced by protistan pathogens. The present invention also relates to a new pyren...
|
|
WO/2017/122495A1 |
A ceramidase inhibitor which comprises a compound represented by formula (I) or a pharmaceutically acceptable salt thereof; and a ceramide synthesis promoter which comprises a compound represented by formula (II) or a pharmaceutically ac...
|
|
WO/2017/118945A1 |
The present invention relates to a premix of dapagliflozin with lactose, processes for its preparation, and pharmaceutical composition thereof. The invention also relates to a process for the preparation of an amorphous dapagliflozin and...
|
|
WO/2017/114102A1 |
The present invention belongs to the field of macromolecules and biomedical materials, and relates to a polymer, a block copolymer comprising a segment of the polymer, methods for preparing the polymer and the block copolymer, a micelle ...
|
|
WO/2017/111380A1 |
The present invention relates to a novel salicylic acid derivative, a method for preparing the same, and a cosmetic composition for whitening comprising the same. The compound exhibits a skin whitening effect by acting on tyrosinase, whi...
|
|
WO/2017/106649A1 |
This disclosure is related to methods for producing anhydroryanodol, ryanodol, or analogues thereof and novel compounds prepared thereby.
|
|
WO/2017/095121A1 |
The present invention relates to a novel hydroxyl pyranone compound, a method for producing same, and a cosmetics composition comprising the compound. The hydroxyl pyranone compound according to the present invention exhibits markedly im...
|
|
WO/2017/095098A1 |
The present invention relates to a novel hydroxyl pyranone compound, a method for producing same, and a cosmetics composition comprising the compound. The hydroxyl pyranone compound according to the present invention exhibits markedly im...
|
|
WO/2017/093209A1 |
The present invention relates to a process for preparing 3-amino tetrahydropyrans and, more particularly, to an improved method for synthesizing a 2,3,5-substituted tetrahydropyran derivative, intermediate being used in the preparation o...
|
|
WO/2017/095319A1 |
The invention relates to compounds of Formula (I), wherein the variables are as defined in the claims, which are useful in the treatment and/or prevention of bacterial infections in a subject. The invention further relates to the use of ...
|
|
WO/2017/084644A1 |
The invention relates to a new crystalline form of Canagliflozin of formula I, with its systematic name (2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)meth
yl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4
,5-triol5 a...
|
|
WO/2017/079867A1 |
There is provided a polymerizable composition, by which discoloration or alignment defects are less likely to occur when a filmy polymer, which is obtained by adding a polymerizable compound to the polymerizable composition and polymeriz...
|
|
WO/2017/083434A1 |
The present teachings relate to pyrone derivatives, pharmaceutical compositions thereof, and methods of using such compounds to treat bacterial infections.
|
|
WO/2017/078927A1 |
Novel compounds having a formula (I), embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a s...
|
|
WO/2017/076264A1 |
The present invention relates to a class of compounds as shown in general formula I or pharmaceutically acceptable salts thereof, a preparation method therefor, application thereof as a small molecule tool that functions as a GPR84 agoni...
|
